Assertio Therapeutics

Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) --…

LAKE FOREST, Ill., July 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective July 1,…

LAKE FOREST, Ill., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company’s Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul…

 Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million Assertio will Pay Antares $18.0 Million Upfront and an Additional $26.0 Million in Deferred Payments Raises Full Year Net Product Sales and Non-GAAP Adjusted EBITDA…

LAKE FOREST, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that on October 28, 2021, the Superior Court of the State of California for the County of Alameda…